Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2009 - 2026)

Vertex Pharmaceuticals has reported Liabilities and Shareholders Equity for 18 years, with the latest figure at $26.5 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 15.75% year-over-year to $26.5 billion; the trailing twelve-month figure through Mar 2026 stood at $101.0 billion (up 15.08% YoY), and the FY2025 full-year result was $25.6 billion, up 13.8% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $26.5 billion, up from $25.6 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $26.5 billion in Q1 2026, with the low at $14.3 billion in Q1 2022.
• Average Liabilities and Shareholders Equity over 5 years is $21.2 billion, with a median of $22.2 billion recorded in 2024.
• Year-over-year, Liabilities and Shareholders Equity jumped 35.13% in 2022 and slipped 4.34% in 2025.
• Tracing VRTX's Liabilities and Shareholders Equity over 5 years: stood at $18.2 billion in 2022, then grew by 25.23% to $22.7 billion in 2023, then dropped by 0.87% to $22.5 billion in 2024, then climbed by 13.8% to $25.6 billion in 2025, then increased by 3.28% to $26.5 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $26.5 billion (Q1 2026), $25.6 billion (Q4 2025), and $24.9 billion (Q3 2025), per Business Quant data.

Peer Comparison